Across TCGA pan-cancer cohorts, NELL2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated NELL2 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher NELL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NELL2 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.
BRCA, STAD, and COAD are the cancer types where NELL2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.